Silo Pharma Inc., a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, has entered into a non-binding letter of intent to form a strategic 50:50 joint venture with Hoth Therapeutics Inc. to develop and commercialize a potential treatment for obesity and metabolic disease based on technology Hoth has exclusively licensed from the U.S. Department of Veterans Affairs (VA) that was co-developed by the VA and Emory University. The novel therapeut...